Monkeypox virus, Interferon, and Necroptosis
Monkeypox virus, Interferon, and Necroptosis
批准号:
10678914
负责人:
Bertram L. Jacobs
金额:
$41.83万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
未结题
起止时间:
2012-05-24 至 2025-07-31
关键词:
AfricaAnimal ExperimentsAnimal ModelAnimalsAttenuatedBindingCaspaseCell DeathCellsCessation of lifeDataDisease OutbreaksE3L geneExposure toFailureFundingGenetic RecombinationGoalsHomologous GeneHumanImmune EvasionIn VitroIncubatedInfectionInterferonsLeadMolecularMonkeypox virusMusN-terminalNucleic Acid BindingOrthopoxvirusPathogenesisPathogenicityPatternPattern recognition receptorPersonsPhosphorylationPhosphotransferasesPoxviridaePrairie DogProteinsRIPK3 geneRegimenResearchResistanceSmallpoxVaccinationVaccinia virusViral PathogenesisVirulenceVirusVirus DiseasesWorkWorld Health OrganizationZoonosescanine modelhuman pathogenin vivoinhibitorloss of function mutationmortalitymutantpathogenpreventprototyperepairedvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Much of what we know about poxvirus innate immune evasion comes from work with the prototype orthopoxvirus, vaccinia virus (VACV). However, it is becoming clear that what we know for VACV is not always true for other poxviruses. The example we have been working on is monkeypox virus (MPXV). VACV has an E3L gene, which is essential for interferon-resistance, both in cells in culture and in the animal model. Despite being highly pathogenic, MPXV is missing 37 residues from the N-terminus of its E3 homologue. Thus, it is surprising that MPXV is as pathogenic as it is, despite missing this essential region of the E3 innate immune evasion protein. We have shown that while the lack of an N-terminal innate immune evasion domain in MPXV allows the virus to be sensed by the host, MPXV has evolved at least two apparently independent mechanisms to overcome the effects of being sensed in cells. The goals of this research are to understand how this unique human pathogen is sensed in infected cells and how it has evolved to counter the effects of sensing. Loss of this innate immune evasion domain makes vaccination against MPXV problematic. The final goal of this project is to develop a vaccine that can safely protect against MPXV infection.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/978-1-0716-1012-1_11
发表时间:
2021
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Cotsmire SM, Szczerba M, Jacobs BL]
通讯作者:
Jacobs BL
A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells.
能够增强哺乳动物细胞中 RNA 表达和蛋白质合成的前导序列。
DOI:
10.1002/pro.2325
发表时间:
2013
期刊:
Protein science : a publication of the Protein Society
影响因子:
--
作者:
[Wellensiek,BrianP, Larsen,AndrewC, Flores,Julia, Jacobs,BertramL, Chaput,JohnC]
通讯作者:
Chaput,JohnC
DOI:
10.1126/scisignal.abq0837
发表时间:
2023-03-14
期刊:
Science signaling
影响因子:
7.3
作者:
[]
通讯作者:
Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response.
具有强大力量的小英雄:疫苗病毒E3蛋白和I型IFN反应的逃避。
DOI:
10.3390/biomedicines10020235
发表时间:
2022-01-22
期刊:
Biomedicines
影响因子:
4.7
作者:
[Szczerba M, Subramanian S, Trainor K, McCaughan M, Kibler KV, Jacobs BL]
通讯作者:
Jacobs BL
DOI:
10.1371/journal.pone.0077879
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Holechek SA, Denzler KL, Heck MC, Schriewer J, Buller RM, Legrand FA, Verardi PH, Jones LA, Yilma T, Jacobs BL]
通讯作者:
Jacobs BL
共 12 条
Monkeypox virus, Interferon, and Necroptosis
-
批准号:10241530
-
项目类别:
-
资助金额:$47.68万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
DsRNA Characterization in Monkeypox-infected Cells
-
批准号:8372121
-
项目类别:
-
资助金额:$38.3万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
Monkeypox virus, Interferon, and Necroptosis
-
批准号:10455608
-
项目类别:
-
资助金额:$54.12万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
DsRNA Characterization in Monkeypox-infected Cells
-
批准号:8653927
-
项目类别:
-
资助金额:$38.3万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
Monkeypox virus, Interferon, and Necroptosis
-
批准号:10052748
-
项目类别:
-
资助金额:$53.83万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
DsRNA Characterization in Monkeypox-infected Cells
-
批准号:8473158
-
项目类别:
-
资助金额:$36.0万
-
财政年份:2012
-
负责人:Bertram L. Jacobs
-
依托单位:
XVII International Poxvirus, Asfivirus and Indorviurs Symposium
-
批准号:8006015
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2010
-
负责人:Bertram L. Jacobs
-
依托单位:
Disabling Vaccinia IFNr: A New Smallpox Vaccine
-
批准号:7491011
-
项目类别:
-
资助金额:$78.44万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Development of a post-exposure vaccine for smallpox
-
批准号:6998645
-
项目类别:
-
资助金额:$109.74万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Disabling Vaccinia IFNr: A New Smallpox Vaccine
-
批准号:7091654
-
项目类别:
-
资助金额:$41.81万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Disabling Vaccinia IFNr: A New Smallpox Vaccine
-
批准号:7285053
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Disabling Vaccinia IFNr: A New Smallpox Vaccine
-
批准号:7283015
-
项目类别:
-
资助金额:$77.77万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Disabling Vaccinia IFNr: A New Smallpox Vaccine
-
批准号:6988269
-
项目类别:
-
资助金额:$49.33万
-
财政年份:2005
-
负责人:Bertram L. Jacobs
-
依托单位:
Development of a Safer Smallpox Vaccine
-
批准号:6802262
-
项目类别:
-
资助金额:$93.26万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Development of a Safer Smallpox Vaccine
-
批准号:7086393
-
项目类别:
-
资助金额:$128.55万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Role of the E3L gene in poxvirus pathogenesis
-
批准号:7159400
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Development of a Safer Smallpox Vaccine
-
批准号:7283126
-
项目类别:
-
资助金额:$112.4万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Role of the E3L gene in poxvirus pathogenesis
-
批准号:6840547
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Role of the E3L gene in poxvirus pathogenesis
-
批准号:7017107
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
Role of the E3L gene in poxvirus pathogenesis
-
批准号:6766775
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2003
-
负责人:Bertram L. Jacobs
-
依托单位:
海外基金